-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Good News! Shijiazhuang Sihua Pharmaceutical Group Has Ranked Among the Top 100 Chinese Pharmaceutical Companies for 2022, Coming in at No. 56.
Category:
发布时间：2023-11-20
【概要描述】
On the joyous occasion of Shijiazhuang Sihua Pharmaceutical Group’s 75th anniversary, the highly anticipated 40th National Pharmaceutical Industry Information Annual Conference and the 2022 Top 100 Chinese Pharmaceutical Companies Forum, held on November 18, solemnly unveiled a series of prestigious rankings, including the “2022 Top 100 Chinese Pharmaceutical Companies” and the “2023 Best Pharmaceutical R&D Pipeline Enterprise in China.” Shijiazhuang Sihua Pharmaceutical Group once again made the “Top 100 Chinese Pharmaceutical Companies” list, ranking 56th, and was also re-elected as one of the “2023 Best Pharmaceutical R&D Pipeline Enterprises in China.”
On the joyous occasion of Shijiazhuang Sihua Pharmaceutical Group’s 75th anniversary, the highly anticipated 40th National Pharmaceutical Industry Information Annual Conference and the 2022 Top 100 Chinese Pharmaceutical Companies Forum, held on November 18, solemnly unveiled a series of prestigious rankings, including the “2022 Top 100 Chinese Pharmaceutical Companies” and the “2023 Best Pharmaceutical R&D Pipeline Enterprise in China.” Shijiazhuang Sihua Pharmaceutical Group once again made the “Top 100 Chinese Pharmaceutical Companies” list, ranking 56th, and was also re-elected as one of the “2023 Best Pharmaceutical R&D Pipeline Enterprises in China.”
It is reported that the annual National Pharmaceutical Industry Information Conference, hosted by the China Pharmaceutical Industry Information Center under the Ministry of Industry and Information Technology, has been held for 40 sessions to date. This year’s conference is themed “Pooling Development Forces to Solidify the Foundation of Health,” with the aim of establishing a high-level platform for exchange and cooperation in the pharmaceutical industry, promoting the development of an innovative, inclusive, and mutually beneficial Chinese pharmaceutical industrial system, and contributing China’s strength to the building of a global community of health for all. The series of rankings of China’s Top 100 Pharmaceutical Companies released at the conference represent the most authoritative industry rankings currently available in China; the companies included are outstanding representatives of the Chinese pharmaceutical industry and epitomize the cutting edge of industry development. Shijiazhuang Sihua Pharmaceutical has been listed on these rankings for many consecutive years, and with its steadily strengthening overall capabilities and continuously improving level of development, its position on the overall ranking has risen steadily.
As a leading domestic pharmaceutical enterprise, Shijiazhuang Sihua Pharmaceutical has, over the past two decades, centered its efforts on transformation, upgrading, and innovative development. By aligning with national priorities and market demands, the company has kept pace with the times, assumed responsibility, and consistently increased its investment in technological innovation. It has strategically aligned its innovation ecosystem with the industrial value chain, leveraged innovation to enhance value, pursued new growth areas, cultivated new competitive advantages, and fostered coordinated development across four key business segments—high-end complex generic drugs, innovative medicines, active pharmaceutical ingredients, and pharmaceutical packaging materials. As a result, its innovation capacity has been significantly strengthened, its industrial structure has continued to optimize, and the dual-circulation model—domestic and international—has accelerated its smooth operation, providing a solid foundation and a powerful growth engine for the company’s leapfrog development. In recent years, the company has demonstrated sustained, healthy, and rapid growth in terms of overall scale, innovation achievements, product mix, and economic performance, firmly placing it on the fast track of high-quality, innovation-driven development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091